Rib-X Adds $5.5M Debt

Xconomy Boston — 

Rib-X Pharmaceuticals, the New Haven, CT-based developer of antibiotics, has raised another $5.5 million in debt and options, according to a regulatory filing. The deal could be worth as much as $15 million over time. We last wrote about Rib-X in March, when Mark Leuchtenberger replaced Susan Froshauer as the company’s CEO. Rib-X, founded in 2000, had raised more than $158 million before the most recent shot of cash.